Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PMN)

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire May 14, 2024

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

GlobeNewswire April 30, 2024

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

GlobeNewswire April 9, 2024

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

GlobeNewswire April 4, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire April 1, 2024

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

GlobeNewswire March 11, 2024

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 22, 2024

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

GlobeNewswire January 22, 2024

ProMIS Neurosciences Issues Letter to Shareholders

GlobeNewswire January 8, 2024
View More News ››

Opinion & Analysis (NDAQ:PMN)

Building a Better Covid-19 Antibody Test

Streetwise Reports May 7, 2020

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial March 28, 2019

Biotech Releases White Paper on Alzheimer's Disease Candidate

Streetwise Reports August 2, 2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Streetwise Reports July 11, 2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

Streetwise Reports June 28, 2018
View More Opinion ››

Bullboard Posts (NDAQ:PMN)

RE:RE:Unanimous 11-0

Yikes, 31% ARIA-E for donanemab  How PMN is still not financed through Ph2 or bought out at this point is beyond me. 
Gbathat - 18 hours ago

Precision Medicine / AI

https://www.fiercebiotech.com/biotech/foresite-raises-900m-make-big-bets-one-best-biotech-investment-environments
goldtech - 2 days ago

RE:RE:RE:Bad news for you.

Scientists all agree soluble toxic oligomers kill neurons, so targeting only the oligomers should stop the propagation of the very toxic...
goldtech - 3 days ago

RE:RE:Bad news for you.

Well ok but what does it change to the fact that eleminating the bad proteins is not the right target?
Alex1726 - 3 days ago

Promis has it correct

We’re advocating that what may be more meaningful across all degenerative diseases is the loss of normal proteins rather than the...
goldtech - 3 days ago

RE:Bad news for you.

He did not explain how the soluble (amyloid beta) normal protein gets generated in the brain to maintain brain function and keep...
G1945V - 3 days ago
View more Bullboard ››

Kootenay Silver Inc.

Kootenay Silver Inc.

Kootenay Silver Inc. is a Canada-based exploration company engaged in the discovery and development of mineral projects in ...
View More »